Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4756 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2006-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0458a0ff01224807ee61f9373c08e623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9855b23e38cc3efc7d29a66a3d549714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_241217caae277724902874b7b85a5374 |
publicationDate |
2008-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20080034922-A |
titleOfInvention |
Method for predicting response to treatment with HERR dimerization inhibitor |
abstract |
The present invention relates to a marker gene or a combination of marker genes selected from the group consisting of epidermal growth factor, transforming growth factor alpha and HER2 marker genes in a biological sample of a patient, or to ampireregulin marker genes and epidermal growth factor, converting growth factor alpha and HER2. Evaluating a combination of marker genes comprising a marker gene selected from the marker gene, and evaluating the results of the first step to predict response to treatment with the HER dimerization inhibitor in the patient. The present invention relates to a method for predicting a response to treatment with an emulation inhibitor. Further described are the uses and methods by which such markers are used. |
priorityDate |
2005-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |